Cancer diagnostics group VolitionRx Ltd (NYSEMKT:VNRX) said its previously-announced share offer has been priced at US$5 a share.
The life sciences company is set to raise around US$11.25mln through the underwritten public offer.
Volition intends to use the net proceeds of the offering for continued product development, clinical studies, product commercialization, working capital, and for other general corporate purposes.
Shares in Volition currently trade at around US$5.55 a share in New York.
Story by ProactiveInvestors